Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy
Journal of Investigative Medicine High Impact Case Reports · 2025-08 · 13
DOI: 10.1177/23247096251368093 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Investigative Medicine High Impact Case Reports, online erschienen am 22.08.2025. Verfasst von Stanley Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: MacNeal Cancer Center, Loyola University Chicago Stritch School od Medicine, Berwyn, IL, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colonic Neoplasms, Adenocarcinoma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) with deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) status represents a highly immunogenic subset that responds well to immune checkpoint inhibitors (ICIs). However, the role of ICIs in resectable, early-stage CRC remains under investigation. We report the case of an 81-year-old woman diagnosed with stage III adenocarcinoma of the right colon, who declined surgery. Immunohistochemistry revealed loss of MLH1 and PMS2, consistent with dMMR. Tumor genomic profiling demonstrated MSI-H, high tumor mutational burden, BRAF V600E, and BRCA2 mutation. Germline testing was negative for BRCA and Lynch syndrome-associated mutations. The patient was treated with neoadjuvant pembrolizumab. After 4 months, mesenteric lymphadenopathy resolved, but focal colonic thickening persisted. The patient again declined surgery. At 10 months of pembrolizumab therapy, PET/computed tomography and colonoscopy showed no residual disease. She developed immune-related adrenal insufficiency, managed with corticosteroids. This case demonstrates complete clinical remission of resectable colon cancer with pembrolizumab alone in a patient with somatic dMMR/MSI-H, BRAF V600E, and BRCA2 mutations. It supports the hypothesis that early use of ICIs—prior to metastatic progression and immune escape—may enhance efficacy. This report highlights the potential for personalized, surgery-sparing treatment strategies in genomically selected CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MacNeal Cancer Center, Loyola University Chicago Stritch School od Medicine, Berwyn, IL, USA.
- Cardinal Bernadin Cancer Center, Loyola University Chicago Stritch School of Medicine Maywood, IL, USA.
ORCID-Profile: Stanley Kim
Zitieren
APA
Kim, S., & Clark, J. I. (2025). Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy. Journal of Investigative Medicine High Impact Case Reports, 13. https://doi.org/10.1177/23247096251368093
Vancouver
Kim S, Clark JI. Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy. Journal of Investigative Medicine High Impact Case Reports. 2025;13. doi:10.1177/23247096251368093
BibTeX
@article{Kim2025,
author = {Kim, Stanley and Clark, Joseph I},
title = {Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy},
journal = {Journal of Investigative Medicine High Impact Case Reports},
year = {2025},
volume = {13},
doi = {10.1177/23247096251368093}
}
EUVIMED